
    
      Study subjects will be treated with standard adjuvant hormonal therapy for a total of 5 years
      or until disease relapse or until HT is permanently discontinued for other reasons. The
      choice of endocrine treatment strategy (drugs to be used or their sequence, if the sequential
      option has been decided) is left at the discretion of the participating site. Adjuvant HT
      will commence after the completion of adjuvant chemotherapy and/or radiotherapy. Percentage
      change (%) from baseline of the blood coagulation parameters at 6, 12, 18, and 24 months of
      treatment. The blood coagulation parameters which will be measured are fibrinogen,
      prothrombin time (PT) and activated partial thromboplastin time (aPTT).
    
  